Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Endo Pharmaceuticals Stories

2012-08-21 10:24:17

CHADDS FORD, Pa., Aug. 21, 2012 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today announced that Blaine Davis, senior vice president corporate affairs, will present a corporate overview at the Stifel Nicolaus 2012 Healthcare Conference on Wednesday, September 5, 2012 at 8:35 a.m. ET. The conference will be held at the Four Seasons in Boston, Massachusetts. A live webcast and audio archive of the presentation will be available on the company's website at http://www.endo.com/. Click...

2012-08-07 02:28:19

CHADDS FORD, Pa., Aug. 7, 2012 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP), announced today that its Board of Directors has authorized the company to repurchase up to $450 million of its common stock through March 2015. The specific timing and number of shares repurchased will be determined by Endo management, at its discretion, and will vary based on market conditions, securities law limitations and other factors. The repurchases will be made using cash resources, and the...

2012-08-07 02:20:27

CHADDS FORD, Pa., Aug 7, 2012 /PRNewswire/ -- Total quarterly revenues of $785 million, increased 29 percent versus prior year Qualitest grows quarterly sales by 20 percent versus prior year Commercial conversion of OPANA(®) ER to new formulation designed to be crush-resistant completed during second quarter Company maintains adjusted diluted EPS in the range of $5.00 to $5.20; Now expects reported diluted (GAAP) EPS in the range of $1.07 to $1.27 Company now expects revenues...

2012-08-02 02:31:41

RALEIGH, N.C. and CHADDS FORD, Pa., Aug. 2, 2012 /PRNewswire-FirstCall/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and Endo Health Solutions Inc. (Nasdaq: ENDP) today announced the initiation of the Phase 3 clinical program for BEMA Buprenorphine for the treatment of moderate to severe chronic pain. The Phase 3 program will consist of two efficacy studies, one in opioid naive and one in opioid experienced subjects. Both studies are anticipated to be completed by...

2012-07-30 02:25:56

CHADDS FORD, Pa., July 30, 2012 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) will announce its second quarter 2012 financial results on August 7, 2012 and will host a conference call and webcast at 8:30 a.m. ET that day to discuss these results. David P. Holveck, president and CEO of Endo, Julie McHugh, chief operating officer, Dr. Ivan Gergel, executive vice president of R&D, Alan Levin, executive vice president and chief financial officer, and Blaine Davis, senior vice...

2012-07-18 23:00:29

On July 13, 2012, Hughes and Coleman filed three lawsuits in the Eastern District of Kentucky and seven lawsuits in the Western District of Kentucky against Pelvic Mesh Manufactures; Boston Scientific Corporation (D/B/A Mansfield Scientific, Ins. & Microvasive, Inc.) Johnson & Johnson, Ethicon, Inc., Ethicon Women´s Health and Urology, Gynecare, American Medical Systems, Inc. Endo Pharmaceuticals and C.R. Bard, Inc., Tissue Science Laboratories Limited for negligence and wrongful...

2012-07-09 02:24:56

RALEIGH, N.C., July 9, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at this year's JMP Securities Healthcare Conference. The presentation is scheduled for Friday, July 13, 2012 at 1:00 p.m. Eastern Time, at The Peninsula Hotel in New York City. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) Dr. Sirgo will focus on BDSI's progress with the clinical...

2012-06-14 02:24:58

SAN ANTONIO, June 14, 2012 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") today announced the appointment of Mr. Steve Carchedi to BioNumerik's Board of Directors. Mr. Carchedi brings extensive pharmaceutical industry and oncology product commercialization experience to the BioNumerik Board. During his more than 29 years in the pharmaceutical industry, he has held key positions in several multi-national pharmaceutical companies and led the commercialization of multiple...

2012-06-08 02:21:58

CHICAGO, June 8, 2012 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VZ, SWN, ENDP, HUM, and GT. To see what our analysts have discovered about these stocks read the InvestorsObserver's PriceWatch Alerts at http://www.investorsobserver.com/pr/6820120 (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks: Verizon (NYSE: VZ), Southwestern Energy (NYSE: SWN), Endo Pharmaceuticals...

2012-05-31 02:25:09

RALEIGH, N.C., May 31, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Jefferies 2012 Global Healthcare Conference in New York City. The presentation is scheduled for Thursday, June 7 at 3:30 P.M. Eastern Time. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) Dr. Sirgo will focus on the clinical development program and timeline for BEMA...